As per newly released report from Absolute Market Insights (AMI), the global cell and gene therapy consumables market is expected to grow at a CAGR of 31.24%, owing to many factors such as rising prevalence of chronic diseases, worldwide disease burden amongst others.
Rising Prevalence of Chronic Diseases
Chronic disease is a disease that persists over a long period of time such as cancer, cardiovascular disease, diabetes and arthritis. Chronic diseases are on rise and currently major cause of death in almost all countries. These diseases are expected to rise by 17% in next 10 years. Studies suggest that cardiovascular diseases are regarded as number one cause of death globally. In 2019, there were 17.9 million deaths due to all types of cardiovascular disease globally. Chronic diseases are significantly influenced by rapid changes in lifestyle and new behavior patterns. The growing urbanization, ageing population and change in societal behavior are contributing to a steady increase in the chronic diseases. The risk factors for chronic disease include infectious agents responsible for cervical and liver cancers, environmental factors like air pollution contributes to asthma and other chronic respiratory diseases, obesity leads to heart stroke and genetic factors also plays a role. Additionally unhealthy diet, physical inactivity and tobacco use attributes to rise in chronic diseases. Three out of five deaths reported globally are due to chronic diseases. The total number of people dying from chronic disease is double than that of infectious diseases such as HIV, tuberculosis and malaria. Healthcare expenditures are greatly increasing with addition of new chronic conditions which includes greater specialist physician access, hospital admission and emergency department presentation. Additionally, there is an increasing demand for the effective therapies due to rising chronic diseases. Gene and Cell therapy are one of the most revolutionary advances of this era. These therapies have the potential to transform entire approach to disease treatment. It treats those diseases for which there is no effective treatment and those that have become resistant to the conventional therapy. These factors are driving the demand for cell and gene therapy consumables market.
Request for Sample Copy of This Report@
https://www.absolutemarketsinsights.com/request_sample.php?id=332
Gene therapy focuses on genetic modification of cells by repairing damaged tissue. It treats wide range of diseases such as cancer, cystic fibrosis, diabetes and many more. Cell therapy is transplantation of cellular material to repair damaged tissue. It treats type 1 diabetes, spinal cord injuries and Parkinson’s disease. Gene and cell therapy is emerging as an important tool to treat human health. These therapies are highly advanced biological products. Many cell and gene therapy products such as chimeric antigen receptor (CAR) T- cell therapies, genetic- modulation based gene therapies and autologous and allogenic cell-based therapies are available for treating rare genetic and chronic diseases. The oncology segment accounts for the highest market share in the global cell and gene therapy consumables market. It is growing at the faster rate on account of rising cases of several types of cancer around the world.
Gene and cell therapy is transforming cancer treatment landscape. It offers opportunity for treating cancer with potential to restore function. According to the WHO, in 2018 ~9.6 million death were reported due to cancer. The first FDA approved gene therapy experiment was conducted in 1990, United States. Since then over 1700 clinical trials have been conducted using various gene therapy techniques. An extensive range of effective vectors, delivery techniques and approaches are driving the cell and gene therapy market. Growing prevalence of chronic diseases is likely to boost cell and gene therapy consumables market.
Enquiry Before Buying@
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=332
Increasing cell and gene therapy trials
Cell and gene therapies have significant effect in disease prevention, diagnosis and management. There has been measurable progress in the fight against chronic diseases using cell and gene therapy. The rising development in cell and gene therapies is leading in a fundamental shift in the biopharmaceutical business model. There are various factors that are driving the cell and gene therapy clinical trials which includes rising patient demand for innovative therapies, growing research and interest in cell and gene therapies for chronic diseases and increase in research & development funding. Cell and gene therapy signify the next great movement of therapeutic innovation and have resulted in promising results globally. Pharmaceutical companies in clinical trials that test cell and gene therapies have witnessed growth over the years. Most notably in oncology, eye diseases and rare genetic diseases. Over past few years cell and gene therapy consumables market has witnessed increasing growth. As per PhRMA in 2019, there were around 362 cell and gene therapies in clinical development in United States. There is 20% increase in clinical trials from 2018. Additionally, by the end of 2019, there were more than 1000 cell and gene therapy clinical trials in process. These clinical trials include 392 gene therapies, 216 cell therapies, 452 gene modified and cell based immune oncology and 46 tissue engineering. In 2021 there are more than 1109 clinical trials underway globally.
Since 2015, there is a rise in the number of clinical trials for evaluation of CAR-T cell therapy. The ClinicalTrials.gov website listed 671 trials for CAR-T cell therapy including 357 trials registered in china, 256 in United States and 58 in other countries. In 2017, FDA signed off the first gene-therapy drug, chimeric antigen receptor (CAR) T-cell for the treatment of acute lymphoblastic leukemia. The growth in CAR-T cell treatment is rising and FDA expects around 10 to 20 cell and gene therapy approvals every year. There are total 3 CAR- T cell therapies available in market. Tisagenlecleucel is the first cell therapy to get approved. These developments are creating huge opportunities for cell and gene therapy consumables market.
Request for Customization@
https://www.absolutemarketsinsights.com/request_for_customization.php?id=332
Cell and Gene Therapy Consumables Market
By Product Type
-
- Kits and Buffers
- Culture Medium
- Natural Media
- Plasma
- Serum
- Lymph
- Human Placental Cord Serum
- Amniotic Fluid
- Others
- Artificial Media
- MEM
- RPMI
- PBS
- DPBS
- HBSS
- EBSS
- Others
- Cryopreservation Media
- Diagnostic Assay
- Others
By Application/Therapeutics
- Cardiovascular
- Dermatology
- Endocrine and Metabolic
- Gastroenterology
- Hematology and Oncology
- Obstetrics
- Critical Care
- Immunology
- Neuroscience
- Respiratory
- Urology
- Others
By Region:
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Get More Information@ https://www.absolutemarketsinsights.com/reports/Cell-and-Gene-Therapy-Consumables-Market-2019-2027-332
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424
Email id: [email protected]
Website: https://www.absolutemarketsinsights.com